[Ip-health] Infojustice Roundup - March 12, 2012

Michael Palmedo mpalmedo at wcl.american.edu
Mon Mar 12 14:20:54 PDT 2012

Infojustice Roundup  
Intellectual Property and the Public Interest


Intellectual Property TPP Talks Stall in Melbourne


Contrasting with the apparent progress on other chapters, which were
declared "on track" by negotiators, the Trans-Pacific Partnership
Agreement's intellectual property chapter appears to have stalled in
Melbourne. According to some sources, the 10 day negotiation yielded no
meaningful progress on the intellectual property chapter as the most
controversial aspects of the U.S. proposal, including internet service
liability and the "May 2007" access to medicines issues, came to the
table. The non-U.S. parties in the negotiation appear to have taken a
uniform stance against many of the U.S.'s more aggressive positions
pressing countries to adopt new rights and enforcement procedures not
contained in any existing U.S. trade agreement. Click here for more.


India Issues Compulsory License for Anti-Cancer Medicine


India has granted Natco Pharmaceuticals a compulsory license to produce
generic sorafenib tosylate - a drug used to treat kidney and liver
cancer that is patented by Bayer and sold under the brand name Nexaver.
Under the terms of the license, Natco will sell the generic drug for a
price not to exceed Rs. 8880 (USD 178) for a one month supply, and will
pay a 6% royalty to Bayer. This is the first compulsory license issued
by the Indian government. Click here for more


USTR Kirk Testifies Before Senate Finance Committee


U.S. Trade Representative Ron Kirk testified before the Senate Finance
Committee on March 7 about the Obama Administration's 2012 Trade Agenda.
Notes from the hearing, instructions on submitting comments to the
Committee and the full webcast are available here
<http://infojustice.org/archives/8763> .  Highlights included: 


*         Sen. Wyden asked Kirk about the consequences of ACTA.  Would
it affect Congress' ability to write future legislation to enhance
competition or to promote innovation on the internet? He further asked
about the Obama Administration's assertion that ACTA does not require
Congressional approval.  Click here for more.

*         Sen. Wyden engaged Kirk on the lack of transparency of the TPP
negotiations, and suggested that USTR place all U.S.-proposed text
relating to internet freedom online.  Click here for the transcript of
this exchange. <http://infojustice.org/archives/8829>  

*         Sen. Menendez asked USTR to propose text on data exclusivity
for the Trans Pacific Parternship at the Dallas negotiating round in
May.  The text should require 12 years of data exclusivity for
biopharmaceuticals. Click here for more.


Finland Delays ACTA Ratification


Finland's EU ministerial committee has postponed ratification of ACTA
until the European Court of Justice completes its review of it. The
Helsingin Sanomat reported that the government won't approve the trade
agreement "until the European Union itself is committed to it."  Last
month, the paper reported protests against ACTA in Helsinki. Click here
for more. <http://infojustice.org/archives/8851/> 


Rep. Issa Calls ACTA an "Unconstitutional Power Grab"


Last week, Rep. Darrell Issa issued a press release blasting the
Anti-Counterfeiting Trade Agreement.  Issa noted that the agreement was
negotiated in secret, may lead to poor consequences for consumers, and
"appears to be an unconstitutional power grab begun by the Executive
Branch to bypass Congress' Constitutional authority over international
commerce and intellectual property rights protections."  He cited a
letter from Senator Wyden to the President objecting to the
Administration's assertion that ACTA does not need Congressional
approval.  Click here for more. <http://infojustice.org/archives/8745> 




More information about the Ip-health mailing list